FMX heads into its July 28 earnings release with call-heavy options activity and a borrow market that's extremely loose — a setup more notable for what's absent than what's extreme.
The lending market signals almost no short-side conviction. Availability for FMX shares is enormous — roughly 26 shares remain available to borrow for every one currently lent out — and the 52-week peak in borrowing demand barely reached 9% utilization. Cost to borrow has picked up over the past month, more than doubling to 0.75%, but even that reading is low in absolute terms and sits on a noisy daily series that spiked briefly to 9% on July 15 before retreating. Short interest itself has edged up about 4% over the past month to roughly 1.87 million shares, a negligible position relative to a company of FEMSA's scale. Options positioning reinforces the call skew: the put/call ratio printed at 0.23 on Thursday, well below its erratic 20-day mean, suggesting the dominant flow into this print has been on the upside.
The bullish case heading into the print rests on a consistent pattern of upward analyst target revisions. Every major firm that has updated its view in 2026 — Barclays, JP Morgan, UBS, and Goldman Sachs — has raised its price target. UBS holds the highest conviction at $139, while JP Morgan's Overweight-rated target sits at $126, just below FMX's current price of $127.12. Barclays sits at $130 with an Equal-Weight, and the consensus mean is $130.56. That picture is coherent: the stock has essentially caught up to where neutral-to-bullish analysts thought it should be. The bear case is less about fundamental deterioration and more about where the valuation goes from here. A P/E around 23x and EV/EBITDA near 56x leave little room for disappointment, particularly with Mexican peso dynamics and inflation as ongoing headwinds to margins across OXXO and Coca-Cola FEMSA volumes.
Historical reactions add a wrinkle worth noting. After last quarter's April 30 release, FMX jumped more than 7% on the day and held most of that gain through the following week. The prior print produced a near-flat day-one reaction. The range of outcomes has been wide enough that the direction of the market's response has depended heavily on the specifics of the quarterly delivery — not just the headline beat or miss.
Monday's report is ultimately a test of whether FEMSA can sustain the margin and volume trajectory that justified seven consecutive analyst target upgrades, at a valuation where the stock has already priced in a lot of good news.
See the live data behind this article on ORTEX.
Open FMX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
